Aptose Biosciences complies with Nasdaq's minimum bid price

Aptose Biosciences has regained compliance with Nasdaq's minimum bid price requirement. The company confirmed that its stock price has been at least $1.00 per share for ten consecutive business days as of March 14, 2025. However, Aptose is still not in compliance with the $2.5 million shareholders' equity requirement. The company is currently operating under an exception that allows additional time to meet this requirement. Aptose is focused on developing treatments for acute myeloid leukemia and other cancers. Its lead drug, tuspetinib, is being tested as a frontline therapy for newly diagnosed patients.